Evidence map›Paper›PMID 36611858›Full record

ArticleCells2022

Construction of a Necroptosis-Related lncRNA Signature for Predicting Prognosis and Immune Response in Kidney Renal Clear Cell Carcinoma.

Yue Zhang, Tongtian Zhuang, Zhenlong Xin, Changjian Sun, Deyang Li, Nan Ma, Xiaoyan Wang, Xuning Wang

Abstract read
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yue ZhangDepartment of Clinical Laboratory, The Air Force Hospital of Northern Theater PLA, Shenyang 110042, China.ORCID 0000-0001-5251-8360
Tongtian ZhuangDepartment of Dermatology, The Air Force Hospital of Northern Theater PLA, Shenyang 110042, China.
Zhenlong XinDepartment of Disease Control and Prevention, The Air Force Hospital of Northern Theater PLA, Shenyang 110042, China.ORCID 0000-0002-2876-4657
Changjian SunDepartment of Clinical Laboratory, The Air Force Hospital of Northern Theater PLA, Shenyang 110042, China.
Deyang LiDepartment of Clinical Laboratory, The Air Force Hospital of Northern Theater PLA, Shenyang 110042, China.ORCID 0000-0002-8694-3557
Nan MaDepartment of Clinical Laboratory, The Air Force Hospital of Northern Theater PLA, Shenyang 110042, China.
Xiaoyan WangDepartment of Clinical Laboratory, The Air Force Hospital of Northern Theater PLA, Shenyang 110042, China.
Xuning WangDepartment of General Surgery, The Air Force Hospital of Northern Theater PLA, Shenyang 110042, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Necroptosis is a new type of programmed cell death and involves the occurrence and development of various cancers. Moreover, the aberrantly expressed lncRNA can also affect tumorigenesis, migration, and invasion. However, there are few types of research on the necroptosis-related lncRNA (NRL), especially in kidney renal clear cell carcinoma (KIRC). In this study, we analyzed the sequencing data obtained from the TGCA-KIRC dataset, then applied the LASSO and COX analysis to identify 6 NRLs (AC124854.1, AL117336.1, DLGAP1-AS2, EPB41L4A-DT, HOXA-AS2, and LINC02100) to construct a risk model. Patients suffering from KIRC were divided into high- and low-risk groups according to the risk score, and the patients in the low-risk group had a longer OS. This signature can be used as an indicator to predict the prognosis of KIRC independent of other clinicopathological features. In addition, the gene set enrichment analysis showed that some tumor and immune-associated pathways were more enriched in a high-risk group. We also found significant differences between the high and low-risk groups in the infiltrating immune cells, immune functions, and expression of immune checkpoint molecules. Finally, we use the "pRRophetic" package to complete the drug sensitivity prediction, and the risk score could reflect patients' response to 8 small molecule compounds. In general, NRLs divided KIRC into two subtypes with different risk scores. Furthermore, this signature based on the 6 NRLs could provide a promising method to predict the prognosis and immune response of KIRC patients. To some extent, our findings helped give a reference for further research between NRLs and KIRC and find more effective therapeutic drugs for KIRC.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsRNA, Long NoncodingHumansImmunityKidneyNecroptosisRNA, Long Noncodingimmune responseKIRClncRNAnecroptosisprognosissignature

Identifiers

PMID36611858
PMCPMC9818734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.